Distinguished in Fibrolamellar Carcinoma

Helmut R. Salih

Otfried Müller Str. 10, 
Tuebingen, BW, DE 
Distinguished in Fibrolamellar Carcinoma
Otfried Müller Str. 10, 
Tuebingen, BW, DE 
OverviewLocationsClinical Research

Overview

Helmut Salih practices in Tuebingen, Germany. Mr. Salih is rated as a Distinguished expert by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Fibrolamellar Carcinoma, Acute Promyelocytic Leukemia, and Bone Marrow Transplant.

His clinical research consists of co-authoring 174 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Fibrolamellar Carcinoma.

Gender
Male

Locations

Otfried Müller Str. 10, Tuebingen, BW 72076, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)
Enrollment Status: Completed
Publish Date: February 23, 2024
Intervention Type: Drug
Study Drugs: Dasatinib, Cytarabine, Daunorubicin, Idarubicin
Study Phase: Phase 3
Phase III Study of Chemotherapy in Combination With ATRA With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia and NPM1 Gene Mutation
Phase III Study of Chemotherapy in Combination With ATRA With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia and NPM1 Gene Mutation
Enrollment Status: Completed
Publish Date: February 27, 2023
Intervention Type: Drug
Study Drug: Gemtuzumab
Study Phase: Phase 3
Phase-II Study Evaluating Midostaurin in Induction, Consolidation and Maintenance Therapy Also After Allogeneic Blood Stem Cell Transplantation in Patients With Newly Diagnosed Acute Myeloid Leukemia Exhibiting a FLT3 Internal Tandem Duplication
Phase-II Study Evaluating Midostaurin in Induction, Consolidation and Maintenance Therapy Also After Allogeneic Blood Stem Cell Transplantation in Patients With Newly Diagnosed Acute Myeloid Leukemia Exhibiting a FLT3 Internal Tandem Duplication
Enrollment Status: Completed
Publish Date: June 04, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 2 Less Clinical Trials

174 Total Publications

T cell-engaging CD276xCD3 bispecific antibody for treatment of endometrial cancer.
T cell-engaging CD276xCD3 bispecific antibody for treatment of endometrial cancer.
Journal: Journal of translational medicine
Published: March 27, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Salih's expertise for a condition
ConditionClose
View All 15 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile